120 related articles for article (PubMed ID: 34425405)
21. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Takashima A; Boku N; Kato K; Nakamura K; Mizusawa J; Fukuda H; Shirao K; Shimada Y; Ohtsu A
Gastric Cancer; 2014; 17(3):522-8. PubMed ID: 24162387
[TBL] [Abstract][Full Text] [Related]
22. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
23. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
24. Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.
Lorenzen S; Herrmann K; Weber WA; Wieder H; Hennig M; Ott K; Bredenkamp R; Peschel C; Schwaiger M; Lordick F
Nuklearmedizin; 2007; 46(6):263-70. PubMed ID: 18084682
[TBL] [Abstract][Full Text] [Related]
25. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
26. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer.
Crumley AB; McMillan DC; McKernan M; Going JJ; Shearer CJ; Stuart RC
Br J Cancer; 2006 Jun; 94(11):1568-71. PubMed ID: 16685271
[TBL] [Abstract][Full Text] [Related]
27. [Hospital of diagnosis influences the probability of receiving curative treatment for oesophageal and gastric cancer].
van Putten M; Verhoeven RHA; Koëter M; van Laarhoven HWM; van Sandick JW; Plukker JTM; Siersema PD; Hulshof MCCM; Wijnhoven BPL; Lemmens VEPP; Nieuwenhuijzen GAP
Ned Tijdschr Geneeskd; 2018; 162():D1970. PubMed ID: 29600921
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.
Schønnemann KR; Yilmaz M; Bjerregaard JK; Nielsen KM; Pfeiffer P
Eur J Cancer; 2012 Mar; 48(4):510-7. PubMed ID: 22244801
[TBL] [Abstract][Full Text] [Related]
29. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.
Hingorani M; Dixit S; Johnson M; Plested V; Alty K; Colley P; Beavis AW; Roy R; Maraveyas A
Cancer Res Treat; 2015 Oct; 47(4):706-17. PubMed ID: 25687854
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
31. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.
Schønnemann KR; Mortensen MB; Bjerregaard JK; Fristrup C; Pfeiffer P
Acta Oncol; 2014 Mar; 53(3):385-91. PubMed ID: 23957622
[TBL] [Abstract][Full Text] [Related]
32. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Schutz FA; Xie W; Donskov F; Sircar M; McDermott DF; Rini BI; Agarwal N; Pal SK; Srinivas S; Kollmannsberger C; North SA; Wood LA; Vaishampayan U; Tan MH; Mackenzie MJ; Lee JL; Rha SY; Yuasa T; Heng DY; Choueiri TK
Eur Urol; 2014 Apr; 65(4):723-30. PubMed ID: 24184025
[TBL] [Abstract][Full Text] [Related]
33. Oesophagectomy rates and post-resection outcomes in patients with cancer of the oesophagus and gastro-oesophageal junction: a population-based study using linked health administrative linked data.
Stavrou EP; Ward R; Pearson SA
BMC Health Serv Res; 2012 Nov; 12():384. PubMed ID: 23136982
[TBL] [Abstract][Full Text] [Related]
34. Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer.
Xu J; Lu D; Zhang L; Li J; Sun G
Cancer Med; 2019 Dec; 8(17):7253-7264. PubMed ID: 31612596
[TBL] [Abstract][Full Text] [Related]
35. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.
Busby J; Murchie P; Murray L; Iversen L; Lee AJ; Spence A; Watson MC; Cardwell CR
Int J Cancer; 2017 Apr; 140(8):1828-1835. PubMed ID: 28120338
[TBL] [Abstract][Full Text] [Related]
36. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
37. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
38. International benchmarking in oesophageal and gastric cancer surgery.
Busweiler LAD; Jeremiasen M; Wijnhoven BPL; Lindblad M; Lundell L; van de Velde CJH; Tollenaar RAEM; Wouters MWJM; van Sandick JW; Johansson J; Dikken JL
BJS Open; 2019 Feb; 3(1):62-73. PubMed ID: 30734017
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
